{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"10"}]}],"title":"AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"10"}]}],"title":"Treatment-related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"5"}]}],"title":"SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"3"}]}],"title":"Treatment-related SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}],"title":"Fatal SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"}]}],"title":"AEs leading to discontinuation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"8"}]}],"title":"AEs requiring dose interruptions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"7"}]}],"title":"AEs requiring dose reductions"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"9"}]}],"title":"AEs requiring dose reductions or interruptions"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Incidence of treatment emergent adverse events is defined as number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes from baseline in vital signs and laboratory results qualifying and reported as AEs. The number of participants in each category is reported in the table.","groups":[{"description":"Participants treated with trametinib 0.0125 mg/kg/day","id":"OG000","title":"Part A - TMT 0.0125 mg/kg/Day"},{"description":"Participants treated with trametinib 0.025 mg/kg/day","id":"OG001","title":"Part A - TMT 0.025 mg/kg/Day"},{"description":"Participants under 6 years of age treated with trametinib 0.032 mg/kg/day","id":"OG002","title":"Part A - TMT 0.032 mg/kg/Day"},{"description":"Participants treated with trametinib 0.04 mg/kg/day","id":"OG003","title":"Part A - TMT 0.04 mg/kg/Day"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"OG004","title":"Part B - Neuroblastoma"},{"description":"Participants with refractory or relapsed neuroblastoma treated with trametinib 0.025 mg/kg/day","id":"OG005","title":"Part B - LGG Fusion"},{"description":"Participants with neurofibromatosis Type -1 associated plexiform neurofibromas (NF-1 with PN) treated with trametinib 0.025 mg/kg/day","id":"OG006","title":"Part B - NF-1 With PN"},{"description":"Participants with BRAF V600 mutant solid tumors treated with trametinib 0.025 mg/kg/day","id":"OG007","title":"Part B - BRAF V600 Mutant Solid Tumor"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who received at least one dose of trametinib in Part A and B","reportingStatus":"POSTED","timeFrame":"From the day of the first dose of trametinib up to 30 days after the last dose, up to maximum duration of 64 months","title":"Incidence of Treatment Emergent Adverse Events in Subjects Treated With Trametinib Monotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}